Triple-drug chemo fails to improve survival in advanced biliary tract cancer

The results of a clinical trial led by researchers at the University of Arizona Health Sciences and published in the Journal of Clinical Oncology showed that chemotherapy combining three different types of drugs did not improve overall survival for patients with advanced stage, inoperable biliary tract cancers.

Risk Adjusted Net Present Value: What is the current valuation of AnaptysBio’s Imsidolimab

The revenue for Imsidolimab is expected to reach an annual total of $14 mn by 2037 in the US based off GlobalData’s Expiry Model. The

August 28, 2023

UVM study links deforestation with higher risk of childhood malaria

Malaria kills more than 600,000 people each year worldwide, and two thirds are children under age five in sub-Saharan Africa.

February 29, 2024

Rafael Holdings and Cyclo Therapeutics enter merger deal

The combined business will focus on advancing treatment for Trappsol Cyclo for Niemann-Pick disease type C1. Credit: Kateryna Kon/Shutterstock. Rafael Holdings has signed a definitive

August 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.